Send to

Choose Destination
MedGenMed. 2001 Sep 7;3(5):9.

Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.

Author information

Chester County Research Center, Chester Springs, Pennsylvania, USA.


In this case report, we report what we believe to be the first case of imatinib mesylate or STI-571 (Novartis) use for treatment of idiopathic hypereosinophilia syndrome (HES). HES is often a fatal illness, damaging the heart, nervous system, lungs, liver, and kidneys. It is often treated with interferon-alpha. In this patient, it was combined with hydroxyurea, and we believe it saved his life. However, he experienced many common side effects, such as a profound intractable headache, severe fatigue, and concentration difficulties. After years on hydroxyurea and interferon-alpha, the severity of these side effects motivated us to try a trial of imatinib mesylate. Its use was followed by an abrupt remission of HES in a few weeks, with no significant side effects.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medscape, Inc.
Loading ...
Support Center